Dr. R.E.W. (Bob) Hancock, OC, OBC, FRSC
Dr. Hancock is a UBC Killam Professor of Microbiology & Immunology, UBC, an Associate Faculty Member of the Wellcome Trust Sanger Institute and a Canada Research Chair in Health and Genomics. His research interests include the systems biology of innate immunity, inflammatory diseases and Pseudomonas aeruginosa, small cationic peptides as novel antimicrobials and modulators of innate immunity, the development of novel treatments for antibiotic resistant infections, and antibiotic uptake and resistance. He has published more than 800 papers and reviews, has 70 patents awarded, and is one of the most highly cited authors in Microbiology and Immunology with more than 117,000 citations and an h-index of 171. He has won several awards including the Aventis Pharmaceuticals ICAAC Award, the leading award for research on antimicrobials, and Canada’s three top prizes for Health Research, and is an Officer of the Order of Canada. He was a co-founder of Migenix, Inimex Pharmaceuticals, ABT Innovations, and the Centre for Drug Research and Development.
Evan Haney, PhD
Chief Scientific Officer
Dr. Haney is an experienced scientist and research coordinator who has managed a team of up to 20 individuals over the past 10 years. He is an inventor on the patents that are core to ASEP’s therapeutic technology and has in-depth experience with the various endeavors relevant to clinical research. He has published more than 40 papers in scientific journals, including two major reviews in Nature journals related to peptide optimization and their development as therapeutics. Dr. Haney holds a Ph.D. in Biochemistry from the University of Calgary.
Chief Financial officer
Jen is an experienced finance and accounting professional. She obtained her CA designation in 2014 from the Canadian Institute of Chartered Accountants while articling with KPMG Vancouver in the technology and telecommunications sector. She has managerial experience in financial planning, analysis and reporting. She has spent her career working with progressive tech companies including Qualcomm Incorporated and has assisted multiple companies through IPO and M&A transactions.